TNFRSF10B and neoplasm: Using 0.5 μg/mL scDb and an E:T ratio of 5:1, significant tumor growth inhibition was obtained in TRAIL-R2-expressing tumor cells with all the PBL preparations tested and with acceptable allogeneic PBL activity, both at 48 and 96 h of incubation (Figure 1A).